Table 3.
Baseline clinical characteristics of patients with and without prior oral anticoagulation therapy after propensity score matching
|
Patients on prior OAC N = 109 |
Patients without prior OAC N = 109 |
P‐value | |
|---|---|---|---|
| Demographic | |||
| Male sex, n (%) | 66 (60.6) | 63 (57.8) | .679 |
| Age (y), median (IQR) | 81 (75‐87) | 83 (74‐88) | .599 |
| Race (Hispanic), n (%) | 4 (3.7) | 3 (2.8) | .781 |
| Comorbidities, n (%) | |||
| Hypertension | 89 (81.7) | 90 (82.6) | .860 |
| Diabetes mellitus | 34 (31.2) | 34 (31.2) | 1.000 |
| Heart failure | 6 (5.5) | 4 (3.7) | .167 |
| Stroke/TIA | 22 (20.2) | 20 (18.3) | .731 |
| Chronic kidney disease | 19 (17.4) | 14 (12.8) | .345 |
| Vascular disease (CAD and/or PAD) | 17 (15.6) | 14 (12.8) | .561 |
| Hypercholesterolaemia | 64 (58.7) | 63 (57.8) | .891 |
| Current smoking habit | 8 (7.3) | 1 (0.9) | .057 |
| COPD/SAHS | 21 (19.3) | 19 (17.4) | .726 |
| Obesity | 20 (18.3) | 20 (18.3) | 1.000 |
| History of malignant disease | 24 (22.0) | 18 (16.5) | .303 |
| Parkinson's disease | 3 (2.8) | 3 (2.8) | 1.000 |
| Any demential level | 4 (3.7) | 11 (10.1) | .511 |
| Any dependency level | 32 (29.4) | 34 (31.2) | .768 |
| Concomitant treatment, n (%) | |||
| Beta‐blockers | 49 (45.0) | 28 (25.7) | .003 |
| Statins | 19 (17.4) | 15 (13.8) | .455 |
| ACEi/ARBs | 60 (55.0) | 68 (62.4) | .271 |
| Antiplatelet therapy | 10 (9.2) | 43 (39.4) | <.001 |
| Laboratory parameters | |||
| Creatinine (mg/dL), median (IQR) | 1.15 (0.89‐1.55) | 1.09 (0.83‐1.58) | .711 |
| Haemoglobin (g/dL), median (IQR) | 13.0 (11.0‐14.0) | 14.0 (12.0‐14.0) | .079 |
| Platelet count (×109/L), median (IQR) | 160.0 (132.0‐206.0) | 175.0 (142.5‐237.0) | .056 |
| Elevated D‐dimer, n (%) | 55 (50.5) | 59 (54.1) | .501 |
| Elevated procalcitonin, n (%) | 26 (23.9) | 18 (16.5) | .186 |
| Elevated C‐reactive protein, n (%) | 102 (93.6) | 99 (90.8) | .340 |
| Elevated troponins, n (%) | 11 (10.1) | 14 (12.8) | .590 |
| Elevated transaminases, n (%) | 43 (39.4) | 36 (33.0) | .333 |
| Elevated ferritin, n (%) | 30 (27.5) | 32 (29.4) | .719 |
| Elevated lactate dehydrogenase, n (%) | 82 (75.2) | 69 (63.3) | .105 |
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; COPD/SAHS, chronic obstructive pulmonary disease/sleep apnoea‐hypopnoea syndrome; IQR, interquartile range; OAC, oral anticoagulant; TIA, transient ischaemic attack.